PBPierre Baumann

Pierre Baumann

*This is an algorithmically generated author record based on publicly available information.

Pierre Baumann has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents

    by Sven Ulrich, Pierre Baumann, Andreas Conca, Hans-Joachim Kuss, Viktoria Stieffenhofer, Christoph Hiemke

    Therapeutic drug monitoring (TDM) has consistently been shown to be useful for optimization of drug therapy. For the first time, a method has been developed for the text analysis of TDM in SPCs in that a catalogue SPC-ContentTDM (SPCCTDM) provides a codification of the content of TDM in SPCs. It consists of six structure-related items (dose, adverse drug reactions, drug interactions, overdose, pregnancy/breast feeding, and pharmacokinetics) according to implicit or explicit references to TDM in paragraphs of the SPC, and four theory-guided items according to the information about ranges of plasma concentrations and a recommendation of TDM in the SPC. The catalogue is regarded as valid for the text analysis of SPCs with respect to TDM. It can be used in the comparison of SPCs, in the comparison with medico-scientific evidence and for the estimation of the perception of TDM in SPCs by the reader. Regarding the approach as a model of text mining, it may be extended for evaluation of other aspects reported in SPCs.

  • The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry

    by P. Baumann, C. Hiemke, S. Ulrich, G. Eckermann, I. Gaertner, M. Gerlach, H.-J. Kuss, G. Laux, B. Müller-Oerlinghausen, M. L. Rao, et al.

    Therapeutic Drug Monitoring (TDM) is a valid tool to optimise pharmacotherapy. It enables the clinician to adjust the dosage of drugs according to the characteristics of the individual patient. In psychiatry, TDM is an established procedure for lithium, some antidepressants and antipsychotics. In spite of its obvious advantages, however, the use of TDM in everyday clinical practice is far from optimal. The interdisciplinary TDM group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) has therefore worked out consensus guidelines to assist psychiatrists and laboratories involved in psychotropic drug analysis to optimise the use of TDM of psychotropic drugs. Five research-based levels of recommendation were defined with regard to routine monitoring of plasma concentrations for dose titration of 65 psychoactive drugs: (1) strongly recommended, (2) recommended, (3) useful, (4) probably useful and (5) not recommended. A second approach defined indications to use TDM, e. g. control of compliance, lack of clinical response or adverse effects at recommended doses, drug interactions, pharmacovigilance programs, presence of a genetic particularity concerning the drug metabolism, children, adolescents and elderly patients. Indications for TDM are relevant for all drugs either with or without validated therapeutic ranges. When studies on therapeutic ranges are lacking, target ranges should be plasma concentrations that are normally observed at therapeutic doses of the drug. Therapeutic ranges of plasma concentrations that are considered to be optimal for treatment are proposed for those drugs, for which the evaluation of the literature demonstrated strong evidence. Moreover, situations are defined when pharmacogenetic (phenotyping or genotyping) tests are informative in addition to TDM. Finally, practical instructions are given how to use TDM. They consider preparation of TDM, analytical procedures, reporting and interpretation of results and the use of information for patient treatment. Using the consensus guideline will help to ensure optimal clinical benefit of TDM in psychiatry.


  • Therapeutic Monitoring of Psychotropic Drugs

    by P. Baumann, C. Hiemke, S. Ulrich, I. Gaertner, M. L. Rao, G. Eckermann, M. Gerlach, H.-J. Kuss, G. Laux, B. Müller-Oerlinghausen, et al.

    TDM of psychotropic drugs is widely used, but there is little consensus regarding its optimal use in the clinical context. This prompted a multidisciplinary group comprised of clinical biochemists, clinical pharmacologists, and psychiatrists of the AGNP (Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie) to provide a consensus guideline. This will allow clinical psychiatrists, practitioners, and laboratory directors involved in psychopharmacotherapy to optimize TDM of antidepressants, antipsychotics, and opioid substituents. Recommendations are also given on the combined use of TDM and pharmacogenetic tests.


  • Pharmacogenetics of chiral psychotropic drugs

    by Pierre Baumann, Chin B. Eap

    Knowledge about the pharmacogenetics of metabolism of psychotropic drugs is based mainly on the study of the polymorphic enzymes CYP2D6 and CYP2C19. This chapter summarizes the knowledge on the pharmacology, metabolism, pharmacokinetics, and pharmacogenetics of antidepressants, antipsychotics, and methadone. Numerous psychotropic drugs are chiral and are introduced as racemates. Chiral drugs have one or several asymmetric centers: at least one carbon (or sulfur) atom of their molecule has four different atoms or groups attached to it. Most psychotropic drugs have active metabolites, and many achiral drugs give rise to chiral metabolites, the formation of which may be stereoselective and depend on the genotype of the patients. Chiral psychotropic drugs represent a useful tool for the study of neuropharmacological mechanisms and of the function of metabolizing enzymes. Many widely used drugs are introduced as racemic compounds, the enantiomers of which clearly differ in their pharmacology, metabolism, and pharmacogenetics.


  • Pharmacogenetics of Psychotropic Drugs

    by Bernard Lerer, Anil K. Malhotra, Thomas A. Ban, Sheldon H. Preskorn, Fabio Macciardi, K. Peter Lesch, Jens Benninghoff, Angelika Schmitt, Colleen M. Niswender, Linda K. Hutchinson, et al.

    Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.


  • Enantiomeric antidepressant drugs should be considered on individual merit

    by Pierre Baumann, Chin B. Eap

    Many antidepressants have been introduced as racemic drugs, the enantiomers of which may differ in some of their pharmacodynamic and pharmacokinetic properties. This review argues that each enantiomer of a chiral antidepressant should be evaluated according to its individual characteristics rather than by extrapolation from the racemate, or by assumptions based on the stereoselective characteristics of other enantiomeric drugs. For example, in some cases the enantiomers' pharmacodynamic and therapeutic properties can be complementary, which suggests that the racemate should be used clinically. In other cases where enantiomers show qualitatively similar but quantitatively different properties to the racemate, using a single enantiomer might be more appropriate. In yet further cases, a distomer may induce the metabolism of the eutomer, enantiomers may be metabolised by different enzymes, there may be a different profile of drug–drug interactions, and therapeutic drug monitoring may be simpler. Therefore, this review exemplifies the principle that each enantiomer of a chiral antidepressant should be evaluated according to its individual pharmacological, pharmacokinetic and pharmacogenetic characteristics. These factors are discussed in relation to five chiral antidepressants: trimipramine, mianserin, mirtazapine, fluoxetine and citalopram. It is hoped that an appreciation of the stereoselective differences between enantiomers will facilitate improvements in the benefit:risk ratio of drugs used in the management of depression. Copyright © 2001 John Wiley & Sons, Ltd.


  • In vitro metabolism of citalopram by monoamine oxidase B in human blood

    by Markus Kosel, Marlyse Amey, Anne-Catherine Aubert, Pierre Baumann


  • Cytochrome P-450 activities in human and rat brain microsomes

    by Pierre Voirol, Michèle Jonzier-Perey, François Porchet, Marianne J. Reymond, Robert C. Janzer, Constantin Bouras, Henry W. Strobel, Markus Kosel, Chin B. Eap, Pierre Baumann


  • An automated procedure for the determination of protein concentration in subcellular fractions

    by Pierre Voirol, Anne-Catherine Aubert, Michèle Jonzier-Perey, Pierre Baumann